Arrowstreet Capital, Limited Partnership Immuno Gen, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $2.34 Million - $3.32 Million	-679,401 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$3.32 - $5.34 $204,883 - $329,542	61,712 Added 9.99%	679,401 $3.13 Million
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $794,022 - $2.55 Million	374,539 Added 154.04%	617,689 $2.11 Million
Q4 2019 Feb 13, 2020	BUY	$2.25 - $5.8 $547,087 - $1.41 Million	243,150 New	243,150 $1.24 Million
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $6.57 Million - $8.39 Million	-690,445 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $2.87 Million - $5.55 Million	428,503 Added 163.59%	690,445 $7.26 Million
Q4 2017 Feb 09, 2018	SELL	$5.07 - $7.92 $2.82 Million - $4.4 Million	-555,674 Reduced 67.96%	261,942 $1.68 Million
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $4.42 Million - $6.93 Million	817,616	817,616 $6.26 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.